Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 6.68 | — | — | — | — | — | — | 0.73 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.73 | 4.12 | 2.07 | 3.08 | 0.74 | 0.42 | 0.76 | 32.50 | 1.01 | 1.23 | 1.59 | 4.18 | 3.40 |
| — | +873.1% | +170.8% | -90.5% | -27.5% | -65.5% | -51.8% | +677.6% | -70.2% | -70.2% | -32.0% | +0.8% | -18.5% | |
| P/B Ratio | — | 2.17 | 0.71 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | 1.39 | — | 0.83 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Coherus Oncology, Inc.'s operating margin was -383.1% in Q3 2025, up 60.5 pp QoQ and down 374.1 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -375.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 4.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.0% | 67.8% | 66.9% | 65.1% | 37.5% | 70.7% | 54.5% | 37.7% | 7.6% | 56.1% | 57.7% | 48.0% | 68.7% |
| — | -4.0% | +22.7% | +72.9% | +392.9% | +25.9% | -5.5% | -21.5% | -88.9% | +150.3% | -29.0% | -43.2% | -17.7% | |
| Operating Margin | -41.8% | -383.1% | -443.6% | -597.9% | -78.0% | -9.0% | -31.6% | -2937.0% | -75.3% | -42.9% | -58.8% | -208.9% | -113.5% |
| — | -4145.5% | -1305.4% | +79.6% | -3.6% | +79.0% | +46.4% | -1306.2% | +33.7% | +75.8% | +19.6% | -55.1% | -110.7% | |
| Net Margin | 10.7% | -307.1% | 2903.9% | -744.4% | -93.6% | -15.2% | -19.9% | 4457.3% | -87.0% | -53.2% | -73.0% | -233.5% | -129.8% |
| — | -1921.4% | +14703.6% | -116.7% | -7.6% | +71.4% | +72.8% | +2009.1% | +33.0% | +72.1% | +12.4% | -46.1% | -108.3% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | -34.2% | 248.5% | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 5.3% | -7.4% | 73.5% | -13.8% | -10.6% | -1.8% | -1.8% | 14.8% | -13.1% | -7.5% | -9.8% | -17.1% | -11.4% |
| — | -307.9% | +4189.6% | -193.5% | +19.0% | +75.8% | +81.7% | +186.1% | -15.0% | +52.4% | -11.7% | -13.6% | -77.3% | |
| ROIC | -85.3% | — | — | -426.7% | -65.9% | -6.9% | -15.8% | -31.4% | -23.0% | -9.7% | -10.4% | -18.6% | -20.5% |
| — | — | — | -1259.9% | -186.3% | +29.0% | -52.0% | -68.7% | -12.2% | +81.5% | +60.5% | +66.8% | +0.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.46 | 0.34 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.21 | 1.23 | 1.43 | 1.22 | 1.21 | 1.25 | 1.21 | 1.17 | 1.43 | 1.85 | 2.28 | 2.56 | 2.75 |
| — | -1.2% | +19.0% | +4.3% | -15.8% | -32.7% | -47.0% | -54.5% | -47.8% | -29.1% | -28.3% | -23.2% | -24.6% | |
| Quick Ratio | 0.96 | 1.23 | 1.42 | 1.20 | 0.96 | 1.09 | 1.07 | 1.05 | 1.24 | 1.58 | 1.90 | 2.16 | 2.47 |
| — | +12.9% | +32.3% | +14.5% | -22.9% | -31.0% | -43.6% | -51.4% | -49.6% | -35.8% | -35.7% | -30.2% | -27.7% | |
| Interest Coverage | -4.11 | -19.07 | -19.98 | -21.13 | -7.90 | -1.19 | -3.84 | -6.10 | -6.49 | -3.12 | -3.47 | -6.98 | -5.49 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCoherus Oncology, Inc.'s current P/E is 6.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Coherus Oncology, Inc.'s current operating margin is -41.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Coherus Oncology, Inc.'s business trajectory between earnings reports.